FDA Extends Xgeva Approval to Include Myeloma Patients with Bone Lesions
The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva‘s (denosumab) approval to include patients with multiple myeloma who have bone lesions. The…
News
Dual-targeted CAR T-cell Therapy Shows Promising Anti-tumor Response in Mice
A preclinical study has shown that a new dual-targeting APRIL CAR T-cell therapy appears to be better at eliminating multiple myeloma cells than conventional CAR T-cell…
Janssen and Legend Biotech Joining Forces to Advance Myeloma CAR T-cell Therapy
Janssen Biotech and China’s Legend Biotech are teaming up to continue developing and to market Legend’s CAR T-cell therapy for multiple myeloma. A hot…
BioLineRx Readies Phase 3 Myeloma Trial to Mobilize Stem Cells for Transplant
BioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux of blood stem cells from…
Biomarker Found That Detects Myeloma Patients Who Will Benefit from Stem Cell Transplant
A collaboration between GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) resulted in the discovery of a biomarker called CHEK1 that detects which…
CellProtect Receives EU Orphan Drug Status for Treatment of Multiple Myeloma
The European Commission has granted orphan drug status to CellProtect as a treatment for multiple myeloma, according to the investigational therapy’s developer, CellProtect…
Adaptimmune Immunotherapy Increases Time It Takes for Myeloma to Progress, Trial Shows
An Adaptimmune therapy that strengthens immune T-cells’ response to cancer has helped patients with advanced myeloma live as long as five years without their disease progressing,…
Weighing Myeloma Cells Could Predict Treatment Responses, MIT Study Shows
Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could…
First Myeloma CAR T-cell Therapy Phase 2 Trial Opens Enrollment
The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma —…
FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns
The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL